Citius Oncology, INC Form 4 insider transactions

Citius Oncology's Director, Robert Joseph Smith, was granted 300,000 restricted stock units, vesting on the third anniversary of the grant date.

Citius Oncology's Director, Dennis M. McGrath, was granted 300,000 restricted stock units vesting on the third anniversary of the grant date.

Citius Oncology's Director, Joel David Mayersohn, was granted 300,000 restricted stock units vesting on the third anniversary of the grant date.

Citius Oncology, Inc. director Suren G. Dutia was granted 300,000 restricted stock units, vesting on the third anniversary of the grant date.

Citius Oncology, Inc. Director Eugene Myron Holuka was granted 300,000 restricted stock units, vesting fully on the third anniversary of the grant date.

Citius Oncology Director Carol Webb received a grant of 300,000 restricted stock units, vesting on the third anniversary of the grant date.

Citius Oncology, Inc. reported an amendment to an insider transaction, granting 850,000 restricted stock units to Director and Secretary Myron Z. Holubiak.

Citius Oncology's Chief Medical Officer, Myron Czuczman, was granted 825,000 restricted stock units, vesting fully on the third anniversary of the grant date.

Citius Oncology's Chief Financial Officer, Jaime Bartushak, was granted 825,000 restricted stock units vesting in 2028.

Citius Oncology's CEO, Leonard L. Mazur, was granted 1.7 million restricted stock units, vesting on the third anniversary of the grant date.

Citius Oncology Director Eugene Myron received a grant of 300,000 restricted common stock shares, vesting in three years.

Citius Oncology, Inc. Director Joel David Mayersohn acquired 300,000 restricted common stock awards, vesting in three years.

Citius Oncology, Inc. Director Carol Webb received a grant of 300,000 restricted common stock awards, vesting in three years.

Citius Oncology Director Dennis M. McGrath was granted 300,000 restricted common stock awards vesting in three years.

Citius Oncology's Chief Financial Officer, Jaime Bartushak, received a grant of 825,000 restricted stock awards, vesting over three years.

Myron Z. Holubiak, a Director and Secretary of Citius Oncology, Inc., was granted 850,000 shares of restricted common stock.

Citius Oncology, Inc. director Robert Joseph Smith was granted 300,000 restricted stock awards, vesting on the third anniversary of the grant date.

Citius Oncology, Inc. Director Suren G. Dutia was granted 300,000 restricted stock awards, vesting on the third anniversary of the grant date.

Citius Oncology's CEO, Leonard L. Mazur, was granted 1.7 million restricted stock awards, vesting on the third anniversary of the grant date.

Citius Oncology's Chief Medical Officer, Myron Czuczman, was granted 825,000 restricted stock awards vesting over three years.

Myron Z. Holubiak, Director and Secretary of Citius Oncology, Inc., reported substantial equity awards, including restricted stock and stock options.

Citius Oncology Director Robert Joseph Smith acquired 300,000 restricted common shares and holds 125,000 stock options, aligning his interests with shareholders.

Citius Oncology's CEO, Leonard L. Mazur, reported the acquisition of 1.7 million restricted common shares and holds significant stock options, reflecting ongoing equity compensation.

Citius Oncology Director Carol Webb reports acquisition of 300,000 restricted common shares and details existing stock options.

Citius Oncology's Chief Medical Officer, Myron Czuczman, reported the acquisition of 825,000 restricted common shares and disclosed existing stock options.

Citius Oncology Director Dennis M. McGrath was granted 300,000 restricted stock awards and holds significant stock options, aligning his interests with shareholders.

Citius Oncology's Chief Financial Officer, Jaime Bartushak, reported significant equity acquisitions, including restricted stock and stock options, signaling increased insider ownership.

Citius Oncology Director Joel David Mayersohn received 300,000 restricted stock awards and holds 250,000 stock options, increasing his direct beneficial ownership.

Citius Oncology Director Suren G. Dutia reported the acquisition of 300,000 restricted common shares and holds 275,000 stock options.

Citius Oncology director Eugene Myron Holuka was granted 300,000 restricted stock awards and holds 275,000 stock options, as detailed in a recent SEC Form 4 filing.